+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Treatment of Inappropriate Secretion of Thyrotropin with Somatostatin Analog SMS 201-995

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Inappropriate thyrotropin secretion (1ST) may originate from either neoplastic disease (nIST) or nonneoplastic resistance to thyroid hormone (nnlST). An inhibitory effect of somatostatin on TSH secretion has been documented. In an attempt to elucidate the possible therapeutic effect of this peptide on nIST and nnlST, a study was conducted in 7 such patients. Sandostatin (SMS 201–995) was administered in daily doses of 100 µg for several days to 1 month. Four patients with nIST responded with a fall in circulating TSH as well as α-subunit with concomitant normalization of free thyroxine and clear symptomatic improvement. In the 3 nnlST patients this effect was considerably less apparent and a partial TSH escape was observed on long-term treatment in 2 cases. The importance of somatostatin and its analogs in the management of thyroid malignancy is stressed.

          Related collections

          Author and article information

          Horm Res Paediatr
          Hormone Research in Paediatrics
          S. Karger AG
          28 November 2008
          : 29
          : 2-3
          : 121-123
          Departments of Endocrinology, Universities of aMilan, bPisa and cRome, Italy
          180986 Horm Res 1988;29:121–123
          © 1988 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 3
          Somatostatin: Recent Advances in Basic Research and Clinical Applications


          Comment on this article